Scholars Central

Conference abstract

How does massively parallel sequencing contribute to biomarker development?

Authors: Andreas Scherer

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The development of validated and qualified preclinical and clinical biomarkers as surrogate endpoints of toxicity or disease or as early diagnostic indicators of disease progression is a complex process. The development of microarrays in the 1990?s had initially raised hopes for faster and possibly more reproducible generation of data which could be used for biomarker discovery, arguably with more or less success. Genomics and related -omics data from massively parallel sequencing (MPS) technologies have to be tested against even higher expectations and are being put under scrutiny. Comparative analyses of microarray data and MPS data will be reviewed, implications and challenges for biomarker development will be discussed.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Pharmacogenomics & Pharmacoproteomics.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Pharmacogenomics & Pharmacoproteomics
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Andreas Scherer”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels